Source:http://linkedlifedata.com/resource/pubmed/id/11425549
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
2001-6-26
|
| pubmed:abstractText |
1,3-Disubstituted isoindolines have been discovered as a new class of potent functional ET(A) selective receptor antagonists through pharmacophore analysis of existing nonpeptide endothelin antagonists. The structure-activity relationships for both the trans and the cis series of isoindolines are discussed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0960-894X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
9
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1737-40
|
| pubmed:dateRevised |
2004-1-20
|
| pubmed:meshHeading | |
| pubmed:year |
2001
|
| pubmed:articleTitle |
Isoindolines: a new series of potent and selective endothelin-A receptor antagonists.
|
| pubmed:affiliation |
Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, 07901, Summit NJ, USA. paivi.kukkola@pharma.novartis.com
|
| pubmed:publicationType |
Journal Article
|